Medical network - on September 20, recently, the four provinces of jiangxi, yunnan, gansu, shanxi issue a notice to the negotiations on the implementation of the national drug, which has, henan, fujian, hubei, anhui, Beijing and other 15 provinces has been clear about the negotiations breeds on provincial medical insurance directory. To this, the experts say, as the domestic innovation drugs and generic drugs through negotiation mechanism into the medical insurance directory and negotiate prices nationwide comprehensive implementation, will be more fierce competition, the future of domestic enterprises and multinational pharmaceutical companies competition, should be more focus on innovation.
According to the relevant provisions of the ministry of human resources social security, the social security department of the provinces (autonomous regions and municipalities) shall not transfer the successful drugs to the health care directory, nor shall they adjust the payment scope. People in the industry say that the 36 special drugs negotiated into the health care catalog cover multiple diseases, and the price cuts are clear. The price advantage of domestic competitive drugs is not obvious.
It is understood that the traditional Chinese medicine and the same kind of imported medicine in the competition usually win at a low price. Now, the import drug has entered the health insurance through the negotiation mechanism, and the price advantage of domestic drug is weakened, and the competitive pressure has increased sharply. At the same time, patients have more leeway to choose medical insurance.
For example, the price range from 7125 yuan/branch before negotiation to RMB 5,700 / branch, with a reduction of 20%, for example, in the case of the company's thunderball resistance 10mg/ml*0.2ml injection. At the same time, the price of the products of the same kind of products in China, such as compaq, 10mg/ml* 0.2ml, was cut from 6,725 yuan/branch before the negotiation to 5555 yuan/branch, a decrease of 17.40%, and the difference between them was only 145 yuan. When lebezumab and compaq are covered, eligible patients can get medicine only by paying 30 percent, which greatly reduces the financial burden.
"At present, in clinical, foreign and domestic generic drugs are used, mainly in the price of the drug behavior. The price gap is narrowing as the health care directory introduces the negotiating mechanism. Wei wenbin, head of ophthalmology at Beijing tongren hospital affiliated to capital medical university, said: "I believe patients will choose medicines that will stand up to clinical trials. Domestic companies must work hard at innovation."
In addition, the negotiation mechanism has become an important way for high-priced innovative drugs to enter the health care directory. The main advantage of drug price negotiation is mutual benefit through consultation and cooperation. Under the traditional directory review mechanism, the negotiation medicine is good in clinical practice, but it is difficult to enter the health care directory because of the high price. The negotiating mechanism provides a way to allow high-priced innovative medicines to be covered by "market space in exchange for price discounts". The drug price negotiation can improve the accessibility of drug use, improve the risk control ability of the insurance fund, guarantee the profits of pharmaceutical enterprises, and promote the development of medical technology.
, deputy director of human resources and social security institute of health research, Mr. Tung said people club department has promised, through negotiations drugs according to the b drugs into management and insurance reimbursement, this is the place to implement, at the same time to do a good job cost monitoring, to prevent the high price of drug abuse. Second, negotiating agreements on 36 kinds of drugs, have paid the price, price fluctuation is unlikely to be significant, therefore responsible for drug bidding procurement around the family planning department for public health shall permit independent public hospital drug procurement negotiations, to avoid the shortage of clinical. In the end, pharmaceutical companies should supply drugs to avoid shortages, and comply with drug marketing regulations to prevent drug abuse.
Dong said that the negotiation mechanism should become the main way for the access of high price innovative medical insurance, which should be normalized in the future. First, we should further standardize the evidence of the negotiations and further refine the procedures, which will help to improve the consensus of the negotiating parties. Second, we will further improve the policy coordination of relevant departments of the government, such as drug circulation, procurement and guarantee policies. Third, pharmaceutical companies should pay more attention to the cost performance of products, and prove the pharmacological value of drugs with scientific and authentic evidence. Fourth, relevant departments and enterprises should also set up around the negotiating drug supply channel, because many is a rare disease of medication through negotiation, the difficulty of the flow and storage of large, high cost, need the government, enterprises, medical institutions and related to the joint efforts of the organization.
|
